Systemic Aspergillosis and Systemic Candidiasis Market is expected to reach US$ 8,247.5 Mn by 2027

Systemic Oral Azoles Segment to Grow at Fast Pace During 2020–2027

According to our latest study on “Systemic Aspergillosis and Systemic Candidiasis Market Forecast to 2027 – COVID-19 Impact and Global Analysis – by Type and Application,” the market is expected to reach US$ 8,247.5 million by 2027 from US$ 6,056.3 million in 2019; it is estimated to grow at a CAGR of 4.0% from 2020 to 2027. The report provides trends prevailing in the global systemic aspergillosis and systemic candidiasis market, and the drivers and hindrances pertaining to the market growth.

Based on type, the systemic aspergillosis and systemic candidiasis market is segmented into voriconazole, liposomal amphotericin b, systemic oral azoles, topical antifungal agents, and others. In 2019, the systemic oral azoles segment held the largest share of the market. The same segment is expected to grow at the fastest rate during the coming years owing to rising number of invasive fungal infections. Oral azole drugs, such as fluconazole, ketoconazole, and itraconazole, have a major advantages in systemic antifungal therapy. Among all three, fluconazole has the most attractive pharmacologic (pharmacokinetics and pharmacodynamic) profile, including the capacity to produce high concentrations of active drug in cerebrospinal fluid and urine.  

Rise in prevalence of fungal diseases and increase in incidence of hospital-acquired fungal infection are the key factors driving the systemic aspergillosis and systemic candidiasis market. Moreover increase in R&D activities and new drug pipeline are likely to have a positive impact on the market in the coming years. However, undiagnosed cases of systemic aspergillosis and systemic candidiasis are restricting the market growth.

Novartis Ag; Sanofi-Aventis; Pfizer, Inc.; Merck And Co., Inc.; Enzon Pharmaceuticals, Inc.; Bayer Ag; Astellas Pharma, Inc.; GlaxoSmithKline Plc; Abbott; and Cipla are among the leading companies operating in the systemic aspergillosis and systemic candidiasis market.  

Global Systemic Aspergillosis and Systemic Candidiasis Market, by Region, 2019 (%)

---

Systemic Aspergillosis and Systemic Candidiasis Market Global Report 2027

Download Free Sample

---

Systemic Aspergillosis and Systemic Candidiasis Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type (Voriconazole, Liposomal, Amphotericin B, Systemic Oral Azoles, Topical, Antifungal Agents, Others); Application (Chronic, Pulmonary Aspergillosis (CPA), Allergic, Bronchopulmonary Aspergillosis (ABPA), Gastrointestinal Candidiasis, Genitourinary Tract Candidiasis, Others), and Geography

The report segments the global systemic aspergillosis and systemic candidiasis market as follows:

By Type

• Systemic Oral Azoles
• Voriconazole
• Liposomal Amphotericin B
• Topical Antifungal Agents
• Others

By Application

• Allergic Bronchopulmonary Aspergillosis (ABPA)
• Chronic Pulmonary Aspergillosis (CPA)
• Gastrointestinal Candidiasis
• Genitourinary Tract Candidiasis
• Others

By Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • France
  • Germany
  • UK
  • Spain
  • Italy
• Asia Pacific (APAC)
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Middle East & Africa (MEA)
  • Saudi Arabia
  • UAE
  • South Africa
• South and Central America (SCAM)
  • Brazil
  • Argentina